Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine A Chu

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
International Journal of Pharmaceutics|May 12, 2009
An interesting relationship between drug absorption and melting pointKatherine A Chu, Samuel H Yalkowsky
Current Drug Metabolism|February 20, 2010
Predicting aqueous solubility: the role of crystallinityKatherine A Chu, Samuel H Yalkowsky
Clinical and Translational Science|April 15, 2023
Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participantsSibel Ucpinar, Patrick F Smith, Li Long, et al.
Clinical and Translational Science|March 18, 2022
A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjectsSibel Ucpinar, Borje Darpo, Ann Neale, et al.
Immunohorizons|July 30, 2021
Preclinical Mechanisms of Topical PRN473, a Bruton Tyrosine Kinase Inhibitor, in Immune-Mediated Skin Disease ModelsYan Xing, Katherine A Chu, Jyoti Wadhwa, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
International Journal of Pharmaceutics|May 12, 2009
An interesting relationship between drug absorption and melting pointKatherine A Chu, Samuel H Yalkowsky
Current Drug Metabolism|February 20, 2010
Predicting aqueous solubility: the role of crystallinityKatherine A Chu, Samuel H Yalkowsky
Clinical and Translational Science|April 15, 2023
Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participantsSibel Ucpinar, Patrick F Smith, Li Long, et al.
Clinical and Translational Science|March 18, 2022
A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjectsSibel Ucpinar, Borje Darpo, Ann Neale, et al.
Immunohorizons|July 30, 2021
Preclinical Mechanisms of Topical PRN473, a Bruton Tyrosine Kinase Inhibitor, in Immune-Mediated Skin Disease ModelsYan Xing, Katherine A Chu, Jyoti Wadhwa, et al.
Pageof 1